A 5-6-7-5 ring system beta acid compound, a preparation method thereof and application thereof in anti-neuroinflammatory drugs

By extracting and purifying novel 5-6-7-5 cyclic β-acid compounds from hops, the problem of the lack of effective anti-neuroinflammatory drugs in the prior art has been solved. Significant inhibitory effect on lipopolysaccharide-induced BV2 cells and high-purity preparation have been achieved, which can be applied to the treatment of various neuroinflammatory-related diseases.

CN121181560BActive Publication Date: 2026-04-14CHINA JAPAN FRIENDSHIP HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511291055.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-09-10
Publication Date
2026-04-14
Estimated Expiration
2045-09-10

AI Technical Summary

Technical Problem

There is a lack of effective novel anti-neuroinflammatory drugs in the current technology, especially compounds that have significant anti-neuroinflammatory effects on lipopolysaccharide-induced BV2 cells.

Method used

Novel 5-6-7-5 ring-based β-acid compounds were extracted and isolated from hops, purified by multi-step chromatographic and analytical techniques to obtain compounds with anti-neuroinflammatory activity, and then combined with conventional pharmaceutical compositions for application.

Benefits of technology

This study provides novel 5-6-7-5 ring-based β-acid compounds with significant anti-neuroinflammatory effects, especially on lipopolysaccharide-induced BV2 cells. These compounds can be used to treat diseases such as depression, Alzheimer's disease, Parkinson's syndrome, Huntington's disease, and peripheral neuritis. Furthermore, the preparation method is simple, reproducible, and has high extraction purity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121181560B_ABST
    Figure CN121181560B_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of medicines, and specifically discloses a novel 5-6-7-5 ring system beta acid compound, a preparation method thereof and application of the compound in resisting neural inflammation. The novel 5-6-7-5 ring system beta acid compound is first separated from nature, has good anti-neural inflammation effect, and can be used for developing medicines for treating neural inflammation related diseases, including but not limited to depression, Alzheimer's disease, Parkinson's syndrome, Huntington's disease, opticospinal neuritis and peripheral neuritis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical technology, and more specifically, relates to a novel class of 5-6-7-5 cyclic β-acid compounds, their preparation methods, pharmaceutical compositions, and their application in drugs for treating neuroinflammatory diseases. Background Technology

[0002] β-acids are a class of natural products with a unique structure and a complex biosynthetic pathway involving phloroglucinol and isopentenyl groups. Due to their novel structure and unique biological activities, they have attracted widespread international attention in recent years. In the search for novel anti-neuroinflammatory drugs, the inventors isolated a new class of 5-6-7-5 ring-based β-acids from dried hop heads and discovered that these compounds possess significant anti-neuroinflammatory activity, comparable to that of the positive control drug dexamethasone, and can be used to develop drugs for treating neuroinflammatory diseases. Summary of the Invention

[0003] In view of the shortcomings of the existing technology, the present invention provides a novel class of 5-6-7-5 cyclic β-acid compounds, their preparation methods, pharmaceutical compositions and applications.

[0004] To achieve the above objectives, the technical solution of the present invention is as follows:

[0005] Novel 5-6-7-5 cyclic β-acid compounds, characterized by having the following structure:

[0006]

[0007] In this application, stereoisomers, tautomers, or pharmaceutically acceptable salts of the 5-6-7-5 ring β-acid compounds are also within the scope of protection of this invention.

[0008] In another aspect, the present invention provides a method for preparing the above-mentioned 5-6-7-5 cyclic β-acid compound, wherein the 5-6-7-5 cyclic β-acid compound is obtained by extraction and separation from hops.

[0009] Furthermore, the preparation method of the 5-6-7-5 cyclic β-acid compound includes the following steps:

[0010] S1. Take the dried aerial parts of hops, add solvent and reflux to extract, combine the extracts and concentrate to obtain the extract;

[0011] S2. After suspending the extract in water, extract it with dichloromethane to obtain the extract;

[0012] S3. The dichloromethane extract was subjected to gradient elution using a petroleum ether-ethyl acetate solution via silica gel column chromatography to obtain fraction AE.

[0013] S4. Fraction C was subjected to gradient elution using petroleum ether-ethyl acetate solution via silica gel column chromatography to obtain fractions C20 and C21, respectively. When identified by silica gel thin-layer chromatography, the Rf value for fraction C20 was 0.27-0.29, and the Rf value for fraction C21 was 0.24-0.26.

[0014] S5. Fraction C20 was subjected to gradient elution using petroleum ether-ethyl acetate solution via silica gel column chromatography to obtain fraction C20.9. When identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C20.9 was 0.43-0.45.

[0015] S6. Fraction C21 was isocratically eluted using Sephadex LH-20 gel column chromatography with dichloromethane-methanol to obtain fraction C21.2; fraction C20.9 was isocratically eluted using Sephadex LH-20 gel column chromatography with methanol to obtain fractions C20.9.1 and C20.9.2; when identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C20.9.1 was 0.55-0.60, the Rf value corresponding to fraction C20.9.2 was 0.56-0.59, and the Rf value corresponding to fraction C21.2 was 0.70-0.75;

[0016] S7. The 5-6-7-5 cyclic β-acid compounds having the structures shown in formula (1) and / or formula (2) were separated from fraction C20.9.2 by HPLC.

[0017] The mobile phase used in the HPLC method is acetonitrile-water solution;

[0018] S8. The 5-6-7-5 ring β-acid compounds having structures as shown in formula (3) and / or formula (4) were separated from fraction C21.2 by HPLC.

[0019] The mobile phase used in the HPLC method is acetonitrile-water solution;

[0020] S9. The 5-6-7-5 ring β-acid compounds having the structures shown in formula (5) and / or formula (6) were separated from fraction C20.9.1 by HPLC.

[0021] The mobile phase used in the HPLC method is acetonitrile-water solution.

[0022] This application uses acetonitrile-water as the mobile phase and employs HPLC to prepare 5-6-7-5 cyclic β-acid compounds with the structural formulas shown in formula (5) and / or formula (6) in fraction C20.9.2 using a C18 column.

[0023] Further, in step S7, the volume ratio of acetonitrile to water in the acetonitrile-water solution is (46:54) to (52:48). Preferably, the volume ratio of acetonitrile to water in the acetonitrile-water solution is 48:52.

[0024] Further, in step S7, fraction C20.9.2 is further separated based on the characteristic ultraviolet absorption (λmax = 274 nm) of the 5-6-7-5 cyclic β-acid observed by HPLC analysis. The retention time of the 5-6-7-5 cyclic β-acid compound with the structural formula as shown in formula (1) is 38-40 min; the retention time of the 5-6-7-5 cyclic β-acid compound with the structural formula as shown in formula (2) is 43-45 min.

[0025] Further, in step S8, based on a total volume of 100, the volume ratio of acetonitrile to water in the acetonitrile-water solution is (45:55) to (50:50). Preferably, the volume ratio of acetonitrile to water in the acetonitrile-water solution is 48:52.

[0026] Further, in step S8, fraction C21.2 is further separated based on the characteristic ultraviolet absorption (λmax = 274nm) of β-acid observed by HPLC analysis, including the retention time of 5-6-7-5 cyclic β-acid compounds with the structural formula as shown in formula (3) for 42-45 min; and the retention time of 5-6-7-5 cyclic β-acid compounds with the structural formula as shown in formula (4) for 47-50 min.

[0027] Further, in step S9, based on a total volume of 100, the volume ratio of acetonitrile to water in the acetonitrile-water solution is (43:57)-(48:52). Preferably, the volume ratio of acetonitrile to water in the acetonitrile-water solution is 45:55.

[0028] Further, in step S9, fraction C20.9.1 is further separated based on the characteristic ultraviolet absorption (λmax = 274 nm) of the 5-6-7-5 cyclic β-acid observed by HPLC analysis, and the retention time of the 5-6-7-5 cyclic β-acid compound with the structural formula as shown in formula (5) is 45-48 min; including the 5-6-7-5 cyclic β-acid compound with the structural formula as shown in formula (6) with a retention time of 51-53 min.

[0029] Further, in step S2, the extract is suspended in 8-15 times its weight of water and then extracted with dichloromethane.

[0030] In this application, the Rf value is the Rf value of the fluorescent spot observed at scanning wavelengths of 254 nm and 365 nm.

[0031] Further, in step S3, based on a total volume of 100, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when washing out fraction C (i.e., the fraction corresponding to C) is (58:42)-(62:38); more preferably, it is 60:40.

[0032] Further, in step S4, based on a total volume of 100, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when washing out fraction C20 (i.e., the fraction corresponding to C20) is (16:84)-(19:81); more preferably, it is 17:83.

[0033] Further, in step S4, based on a total volume of 100, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when washing out fraction C21 (i.e., the fraction corresponding to C21) is (14:86)-(16:84), more preferably 15:85.

[0034] Further, in step S5, based on a total volume of 100, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when fraction C20.9 is washed out (i.e., the volume corresponding to fraction C20.9) is (35:65)-(45:55); more preferably it is 40:60.

[0035] Further, in step S6, based on a total volume of 100, the volume ratio of dichloromethane to methanol in the dichloromethane-methanol solution when washing out fraction C21.2 (i.e., the fraction corresponding to C21.2) is (6:4) to (3:7), more preferably 5:5.

[0036] Further, in step S1, the solvent is an 88-98 V% aqueous ethanol solution; the solvent added is 8-10 times the mass of hops, and the reflux extraction is performed 1-3 times, with each extraction lasting 1-3 hours.

[0037] In another aspect, the present invention provides a pharmaceutical composition containing the above-mentioned novel 5-6-7-5 cyclic β-acid compounds.

[0038] Furthermore, the pharmaceutical composition includes other active ingredients and pharmacodynamically acceptable carriers or excipients.

[0039] In other words, pharmaceutical compositions containing the 5-6-7-5 cyclic β-acid compounds of the present invention as active ingredients and conventional pharmaceutical excipients or carriers are also included in the present invention.

[0040] Furthermore, the other active ingredients are one or more of the following substances:

[0041] Aspirin, ibuprofen, indomethacin, naproxen, nabumetone, piroxicam, phenylbutazone, diclofenac, fenprofen, ketobuprofen, ketorolac, tetraclofenamic acid, sulindac, tometidine, fenbufen, sulindac, celecoxib, dexamethasone, prednisone, methylprednisolone, cortisone.

[0042] Furthermore, the dosage form of the pharmaceutical composition is tablets, capsules, granules, oral liquids, powders, drops, or micro-pellets.

[0043] In another aspect, the present invention provides the use of the above-mentioned novel 5-6-7-5 cyclic β-acid compounds and / or the above-mentioned compositions in the preparation of drugs for treating neuroinflammatory diseases.

[0044] For a more concise description, this application will name the compounds having formulas (1)-(6) respectively as compound (±)-humulunone AC.

[0045] Compared with the prior art, the present invention has the following advantages:

[0046] (1) This invention provides a novel 5-6-7-5 cyclic β-acid compound (±)-humulunones AC that has not been reported before, which has good anti-neuroinflammatory effects; particularly significantly, the 5-6-7-5 cyclic β-acid compounds (+)-humulunone A, (-)-humulunone A, (+)-Humulunone B, (-)-Humulunone B, (+)-Humulunone C and (-)-Humulunone C provided by this invention have significant anti-neuroinflammatory effects on lipopolysaccharide-induced BV2 cells, and can be used to develop drugs for the treatment of neuroinflammatory-related diseases, including but not limited to depression, Alzheimer's disease, Parkinson's syndrome, Huntington's disease, neuromyelitis optica, peripheral neuritis, etc.

[0047] (2) The preparation method of the novel 5-6-7-5 ring system β acid compound (±)-humulunones AC is simple to operate, has good reproducibility, and has high extraction purity. Attached Figure Description

[0048] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0049] Figure 1The (+)-humulunone A obtained in Example 1 of this invention 1 1H NMR spectrum (400 MHz, CDCl3);

[0050] Figure 2 The (+)-humulunone A obtained in Example 1 of this invention 13 C NMR spectrum (100 MHz, CDCl3);

[0051] Figure 3 The HMBC spectrum of (+)-humulunone A obtained in Example 1 of this invention;

[0052] Figure 4 The (-)-humulunone A obtained in Example 1 of this invention 1 1H NMR spectrum (400 MHz, CDCl3);

[0053] Figure 5 The (-)-humulunone A obtained in Example 1 of this invention 13 C NMR spectrum (100 MHz, CDCl3);

[0054] Figure 6 The HMBC spectrum of (-)-humulunone A obtained in Example 1 of this invention;

[0055] Figure 7 The (+)-humulunone B obtained in Example 2 of this invention 1 1H NMR spectrum (400 MHz, CDCl3);

[0056] Figure 8 The (+)-humulunone B obtained in Example 2 of this invention 13 C NMR spectrum (100 MHz, CDCl3);

[0057] Figure 9 The HMBC spectrum of (+)-humulunone B obtained in Example 2 of this invention;

[0058] Figure 10 The (-)-humulunone B obtained in Example 2 of this invention 1 1H NMR spectrum (400 MHz, CDCl3);

[0059] Figure 11 The (-)-humulunone B obtained in Example 2 of this invention 13C NMR spectrum (100 MHz, CDCl3);

[0060] Figure 12 The HMBC spectrum of (-)-humulunone B obtained in Example 2 of this invention;

[0061] Figure 13 The (+)-humulunone C obtained in Example 3 of this invention 1 1H NMR spectrum (400 MHz, CDCl3);

[0062] Figure 14 The (+)-humulunone C obtained in Example 3 of this invention 13 C NMR spectrum (100 MHz, CDCl3);

[0063] Figure 15 The HMBC spectrum of (+)-humulunone C obtained in Example 3 of this invention;

[0064] Figure 16 The (-)-humulunone C obtained in Example 1 of this invention 1 1H NMR spectrum (400 MHz, CDCl3);

[0065] Figure 17 The (-)-humulunone C obtained in Example 1 of this invention 13 C NMR spectrum (100 MHz, CDCl3);

[0066] Figure 18 The HMBC spectrum of (-)-humulunone C obtained in Example 1 of this invention. Detailed Implementation

[0067] The technical solution of the present invention will now be clearly and completely described with reference to the accompanying drawings. Obviously, the described embodiments are only some, not all, of the embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0068] The present invention will be further explained below with reference to specific embodiments.

[0069] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to embodiments.

[0070] It should be understood that the specific embodiments described herein are for illustrative purposes only and are not intended to limit the scope of the invention.

[0071] In the embodiments, unless otherwise specified, all methods used are conventional methods in the art.

[0072] The terms “comprising,” “including,” or any other variations thereof, as used herein, are intended to cover non-exclusive inclusion. For example, a composition, step, method, article, or apparatus that includes the listed elements is not necessarily limited to those elements, but may include other elements not expressly listed or elements inherent to such composition, step, method, article, or apparatus.

[0073] Where specific techniques or conditions are not specified in the examples, they shall be performed in accordance with the techniques or conditions described in the literature in this field, or in accordance with the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased through legitimate channels.

[0074] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0075] Furthermore, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0076] Example 1

[0077] This embodiment discloses a method for preparing a novel 5-6-7-5 cyclic β-acid compound, comprising the following steps:

[0078] S1. Take the dried aerial parts of hops, add solvent and reflux extract, combine the extracts and concentrate to obtain an extract; specifically, the solvent is an 88-98 V% aqueous ethanol solution; the mass of the solvent added is 8-10 times that of the hops, the reflux extraction is performed 1-3 times, and each extraction is performed for 1-3 hours.

[0079] The specific implementation plan is as follows: Weigh 208 kg of dried aerial parts of hops, add 10 times the mass of 95% ethanol aqueous solution as solvent and reflux extract three times, each extraction for 2 hours, combine the extracts and concentrate to obtain an extract (about 9.0 kg).

[0080] S2. After suspending the extract in water, extract it with dichloromethane to obtain the extract;

[0081] Further, in step S2, the extract is suspended in 8-15 times its weight of water and then extracted with dichloromethane.

[0082] The specific steps are as follows: After suspending the extract (9.0 kg) in 10 times its weight of water (90 L), extract it with 1.5 times its volume of dichloromethane. Extract three times to obtain dichloromethane extract (about 3100 g).

[0083] S3. The extract was subjected to gradient elution using a petroleum ether-ethyl acetate solution via silica gel column chromatography to obtain fraction C. When identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C was 0.55-0.62. Based on a total volume of 100, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when fraction C was eluted was (58:42)-(62:38); more preferably, the volume ratio was 60:40.

[0084] It should be noted that elution with a petroleum ether-ethyl acetate solution at a volume ratio of (58:42)–(62:38) and identification of fraction C with an Rf value of 0.55–0.62 using silica gel thin-layer chromatography were employed. The volume ratio of the petroleum ether-ethyl acetate solution required to obtain fraction C was between (58:42) and (62:38), with the highest efficiency achieved when eluting with a petroleum ether-ethyl acetate solution at a volume ratio of 60:40. The following gradient elution principles are essentially the same.

[0085] In this application, the Rf value is the Rf value of the fluorescent spot observed at scanning wavelengths of 254 nm and 365 nm.

[0086] The specific steps are as follows: The dichloromethane extract was subjected to silica gel column chromatography, using a petroleum ether-ethyl acetate gradient elution at volume ratios of 100:0, 90:10, 80:20, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, and 0:100, with each 500 mL volume representing one fraction. Thirty-five fractions were obtained sequentially: 1-5, 6-10, 11-25, 26-29, and 30-35. These fractions were identified using silica gel thin-layer chromatography, based on 254 nm and 365 nm. Fluorescent spots with Rf values ​​of 0.81-0.83 (fractions 1-5), 0.78-0.80 (fractions 6-10), 0.75-0.77 (fractions 11-25), 0.72-0.74 (fractions 26-29), and 0.65-0.68 (fractions 30-35) observed at nm were combined to obtain five fractions, named A, B, C, D, and E respectively; among them, fraction C was obtained by combining fractions 11-25.

[0087] The characteristic ultraviolet absorption (λ) of 5-6-7-5 ring β acids observed by HPLC analysis max = 274 nm) Select fraction C for the next separation step.

[0088] S4. Fraction C is eluted by gradient elution using a petroleum ether-ethyl acetate solution via silica gel column chromatography to obtain fraction C20. When identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C20 is 0.27-0.29. The volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when fraction C20 is eluted (i.e., the volume ratio corresponding to fraction C20) is (16:84)-(19:81), preferably 17:83.

[0089] The specific operating steps include: passing fraction C through silica gel column chromatography, using a petroleum ether-ethyl acetate gradient elution with volume ratios of 100:0, 95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, 50:50, 45:55, 40:60, 35:65, 30:70, 27:73, 25:75, 22:78, 20:80, 17:83, 15:85, 12:88, 10:90, 5:95, and 0:100 to sequentially obtain fraction 1- 4, 5-8, 9-14, 15-18, 19-23, 24-30, 31-34, 35-41, 42-49, 50-55, 56-64, 65-71, 72-75, 76-80, 81-90, 91-100, 101-105, 106-109, 110-115, 116-119, 120-124, 125-130, 131-135, 136-138, 139-142, a total of 142 fractions, were then identified using silica gel thin-layer chromatography, based on wavelengths of 254 nm and 365 nm. The Rf values ​​of the fluorescent spots observed at nm were 0.84-0.88 (fractions 1-4), 0.80-0.83 (fractions 5-8), 0.76-0.78 (fractions 9-14), 0.72-0.75 (fractions 15-18), 0.68-0.70 (fractions 19-23), 0.64-0.67 (fractions 24-30), and 0.61-0.63 (fractions 19-23). Fractions 31-34, 0.57-0.59 (fraction 35-41), 0.52-0.55 (fraction 42-49), 0.49-0.51 (fraction 50-55), 0.46-0.48 (fraction 56-64), 0.46-0.47 (fraction 65-71), 0.44-0.45 (fraction 72-75), 0.42-0.43 (fraction 76) -80), 0.39-0.41 (fraction 81-90), 0.37-0.38 (fraction 91-100), 0.35-0.36 (fraction 101-105), 0.33-0.34 (fraction 106-109), 0.30-0.32 (fraction 110-115), 0.27-0.29 (fraction 116-119), 0.24-0. Fractions 26 (120-124), 0.21-0.23 (125-130), 0.20-0.22 (131-135), 0.18-0.19 (136-138), and 0.15-0.17 (139-142) are combined to obtain fractions C1-C25; among them, fractions 116-119 are combined to form fraction C20.

[0090] S5. Using a petroleum ether-ethyl acetate solution, fraction C20 is eluted by gradient elution using silica gel column chromatography to obtain fraction C20.9. When identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C20.9 is 0.43-0.45. The volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution eluted from fraction C20.9 (i.e., the fraction corresponding to C20.9) is (35:65)-(45:55), preferably 40:60.

[0091] Specific procedures include: analyzing the characteristic ultraviolet absorption (λ) of β-acids observed by HPLC. max = 274 nm) C20 was selected for further separation. Fraction C20 was subjected to silica gel column chromatography using a petroleum ether-ethyl acetate gradient elution at volume ratios of 100:0, 95:5, 90:10, 85:15, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, and 0:100. Sixty fractions (1-5, 6-10, 11-15, 16-20, 21-25, 26-31, 32-35, 36-41, 42-46, 47-51, 52-55, and 56-60) were collected sequentially and identified by silica gel thin-layer chromatography at wavelengths of 254 nm and 365 nm. The Rf values ​​of the fluorescent spots observed at nm were 0.83-0.85 (fractions 1-5), 0.79-0.82 (fractions 6-10), 0.75-0.78 (fractions 11-15), 0.71-0.73 (fractions 16-20), 0.67-0.69 (fractions 21-25), 0.63-0.66 (fractions 26-31), 0.54-0.62 (fractions 32-35), 0.47-0.50 (fractions 36-41), 0.43-0.45 (fractions 42-46), 0.36-0.40 (fractions 47-51), 0.31-0.34 (fractions 52-55), and 0.26-0.29 (fractions 56-60). These values ​​were combined to obtain 12 fractions, C20.1-C20.12. Among them, fractions 42-46 are combined to form fraction C20.9.

[0092] S6. Fraction C20.9 was isocratically eluted with methanol using Sephadex LH-20 gel column chromatography to obtain fraction C20.9.2. When identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C20.9.2 was 0.70-0.75.

[0093] The specific procedures include: analyzing the characteristic ultraviolet absorption (λ) observed by HPLC. max= 274 nm) C20.9 was selected for further separation. Fraction C20.9 was subjected to Sephadex LH-20 gel column chromatography with isocratic elution using pure methanol, and 35 fractions (1-10, 11-15, 16-20, 21-25, 26-35) were collected sequentially. Silica gel thin-layer chromatography was used for identification. Based on the Rf values ​​of the fluorescent spots observed at wavelengths of 254 nm and 365 nm, which were 0.77-0.82 (fractions 1-10), 0.70-0.75 (fractions 11-15), 0.62-0.69 (fractions 16-20), 0.53-0.59 (fractions 21-25), and 0.42-0.48 (fractions 26-35), respectively, five fractions were combined to obtain C20.9.1~C20.9.5. Among them, fractions 11-15 are combined to form fraction C20.9.2.

[0094] S7. The 5-6-7-5 ring β-acid compounds having structures as shown in formula (1) and / or (2) were separated from fraction C20.9.2 by HPLC.

[0095] The mobile phase used in the HPLC method is acetonitrile-water solution.

[0096] This application uses acetonitrile-water as the mobile phase and employs HPLC method, utilizing C 18 The chromatographic column was used to prepare 5-6-7-5 cyclic β-acid compounds with the structural formulas shown in formulas (1) and (2) in fraction C20.9.2.

[0097] Wherein, the volume ratio of acetonitrile to water in the acetonitrile-water solution is (46:54) to (52:48). Preferably, the volume ratio of acetonitrile to water in the acetonitrile-water solution is 48:52.

[0098] The characteristic ultraviolet absorption (λ) of β-acids observed by HPLC analysis max = 274 nm) Further separation of fraction C20.9.2 was performed, including 5-6-7-5 cyclic β-acid compounds with the structural formula as shown in formula (1) with a retention time of 38-40 min (purity: 98%).

[0099] In addition, the retention time of 5-6-7-5 cyclic β-acid compounds with the structural formula shown in formula (2) is 43-45 min (purity: 98%).

[0100] The physical properties and detection data of compound 1 obtained in Example 1 are as follows:

[0101] Pale yellow prismatic crystals, readily soluble in dichloromethane and methanol. High-resolution mass spectrometry (HR-ESI-MS) m / z 449.2534 ([M +H])+ The calculated value is 449.2495, suggesting the molecular formula of the compound is C. 25 H 36 O7 has an unsaturation degree of 8.

[0102] 1 1H NMR (CDCl3, 400 MHz) spectrum Figure 1 This indicates the presence of a hydrogen proton signal connected to an electron-withdrawing group in the low-field region. d H 4.66 (1H, t, J = 8.4 Hz, H-11); there are 3 sets of methylene proton signals in the high field region [ d H 3.36 (1H, dd, J =13.9, 7.5 Hz, H-12), 2.10 (1H, dd, J = 14.0, 8.5 Hz, H-12), 2.22 (1H, dd, J =12.9, 9.1 Hz, H-14), 2.36 (1H, t, J = 12.2 Hz, H-14), 1.82 (1H, t, J = 12.0 Hz, H-16), 2.78 (1H, dd, J = 6.9, 11.5 Hz, H-16), 6 single-peak methyl proton signals [ d H 1.35, 1.30, 1.27, 1.25, 1.23, 0.84 (each 3H, s)], two bimodal methyl proton signals [ d H 1.09, 1.08 (each 3H, overlapped, CH3-21, 22)]. The above information suggests that this compound may be a β-acid compound.

[0103] 13 The C10 NMR (CDCl3, 100 MHz) spectrum showed a total of 25 carbon signals ( Figure 2 ), including 3 carbonyl carbon signals ( d C 205.9, 190.6, 170.8), a pair of olefin carbon signals ( d C 176.9, 115.3), 4 oxygen-carbon signals ( d C 92.5, 90.6, 73.1, 71.5), 3 sp 3 Hybridized methylene carbon signal ( d C 35.8, 35.0, 33.6), 8 methyl carbon signals ( d C The information above (30.7, 30.0, 28.1, 26.7, 25.9, 25.5, 18.1, 17.5) suggests that compound 1 may contain a furan ring formed by the cyclic combination of an isopentenyl group and an enol hydroxyl group, a 1-carbonyl isobutyl segment, two 2-hydroxyisopropyl segments, and a lactone ring.

[0104] 1 H NMR, 13 The signal assignments for C NMR are shown in Table 1.

[0105] Table 1. NMR data of compound 1 d (ppm)

[0106]

[0107] HMBC Map ( Figure 3 In ), H-5 ( d H 2.78) and C-6 ( d C 91.2), C-3 ( d C 73.1), C-4 ( d C 56.0), C-15 ( d C 56.4), C-16 ( d C The long-range correlation of 39.1) proves the connection between the five-membered and seven-membered rings at C-6 and C-15, and also proves the presence of a 2-hydroxyisopropyl fragment at position 4, which also indirectly confirms the presence of a pair of geminal dimethyl groups at position C-16; H-12 ( d H 3.36) and C-9 ( d C 176.9), C-13 ( d C The long-range correlation of 56.0 proves the connection between the five-membered furan ring and the seven-membered ring at C-9 and C-13, and this connection is also demonstrated through H-14 ( d H 2.36 and C-9 ( d C 176.9), C-12 ( d C33.6), C-13 ( d C The long-range correlation of H-12 (56.0) is corroborated; d H 3.36) and C-11 ( d C 92.5), C-23 ( d C The correlation of 71.5) confirms the linkage of the 2-hydroxyisopropyl fragment at the C-11 position, H-12 ( d H 3.36) and H-14 ( d H The correlation between 2.36 and C-27 (170.8) further confirmed the connection of the lactone ring at C-6 and C-13. Long-range correlation of the high-field region 4 composition with the methyl proton signal confirmed the connection positions of the 1-carbonyl isobutyl segment, two 2-hydroxyisopropyl segments, and a set of geminal dimethyl segments. Based on the above information, the planar structure of compound 1 was deduced, suggesting it is a β-acid derivative. Comparison of calculated circular dichroism (ECD) data with measured ECD data confirmed the absolute configuration of the compound to be 4. S 6 R ,11 R ,13 R 15 R .

[0108] In summary, the structure of the new compound 1 (i.e., compound (+)-humulunone A) is determined as follows:

[0109] .

[0110] The physical properties and detection data of compound 2 obtained in Example 1 are as follows:

[0111] Pale yellow prismatic crystals, readily soluble in dichloromethane and methanol. High-resolution mass spectrometry (HR-ESI-MS) m / z 449.2534 ([M +H]) + The calculated value is 449.2495, suggesting the molecular formula of the compound is C. 25 H 36 O7 has an unsaturation degree of 8.

[0112] 1 1H NMR (CDCl3, 400 MHz) spectrum Figure 4 This indicates the presence of a hydrogen proton signal connected to an electron-withdrawing group in the low-field region. d H 4.66 (1H, t, J = 8.4 Hz, H-11); there are 3 sets of methylene proton signals in the high field region [ d H 3.36 (1H, dd, J =13.9, 7.5 Hz, H-12), 2.10 (1H, dd, J = 14.0, 8.5 Hz, H-12), 2.22 (1H, dd, J =12.9, 9.1 Hz, H-14), 2.36 (1H, t, J = 12.2 Hz, H-14), 1.82 (1H, t, J = 12.0 Hz, H-16), 2.78 (1H, dd, J = 6.9, 11.5 Hz, H-16), 6 single-peak methyl proton signals [ d H 1.35, 1.30, 1.27, 1.25, 1.23, 0.84 (each 3H, s)], two bimodal methyl proton signals [ d H 1.09, 1.08 (each 3H, overlapped, CH3-21, 22)]. The above information suggests that this compound may be a β-acid compound.

[0113] 13 The C10 NMR (CDCl3, 100 MHz) spectrum showed a total of 25 carbon signals ( Figure 5 ), including 3 carbonyl carbon signals ( d C 205.9, 190.6, 170.8), a pair of olefin carbon signals ( d C 176.9, 115.3), 4 oxygen-carbon signals ( d C 92.5, 90.6, 73.1, 71.5), 3 sp 3 Hybridized methylene carbon signal ( d C 35.8, 35.0, 33.6), 8 methyl carbon signals ( d C The information above (30.7, 30.0, 28.1, 26.7, 25.9, 25.5, 18.1, 17.5) suggests that compound 2 may contain a furan ring formed by the cyclic combination of an isopentenyl group and an enol hydroxyl group, a 1-carbonyl isobutyl segment, two 2-hydroxyisopropyl segments, and a lactone ring.

[0114] 1 H NMR, 13 The signal assignments for C NMR are shown in Table 2.

[0115] Table 2 NMR data of compound 2 d (ppm)

[0116]

[0117] HMBC Map ( Figure 6 In ), H-5 ( d H 2.78) and C-6 ( d C 91.2), C-3 ( d C 73.1), C-4 ( d C 56.0), C-15 ( d C 56.4), C-16 ( d C The long-range correlation of 39.1) proves the connection between the five-membered and seven-membered rings at C-6 and C-15, and also proves the presence of a 2-hydroxyisopropyl fragment at position 4, which also indirectly confirms the presence of a pair of geminal dimethyl groups at position C-16; H-12 ( d H 3.36) and C-9 ( d C 176.9), C-13 ( d C The long-range correlation of 56.0 proves the connection between the five-membered furan ring and the seven-membered ring at C-9 and C-13, and this connection is also demonstrated through H-14 ( d H 2.36 and C-9 ( d C 176.9), C-12 ( d C 33.6), C-13 ( d C The long-range correlation of H-12 (56.0) is corroborated; d H 3.36) and C-11 ( d C 92.5), C-23 ( d C The correlation of 71.5) confirms the linkage of the 2-hydroxyisopropyl fragment at the C-11 position, H-12 ( d H 3.36) and H-14 ( d HThe correlation between 2.36 and C-27 (170.8) further confirmed the connection of the lactone ring at C-6 and C-13. Long-range correlation of the high-field region 4 composition with the methyl proton signal confirmed the connection positions of the 1-carbonyl isobutyl segment, two 2-hydroxyisopropyl segments, and a set of geminal dimethyl segments. Based on the above information, the planar structure of compound 2 was deduced, suggesting it is a β-acid derivative. Comparison of calculated circular dichroism (ECD) data with measured ECD data confirmed the absolute configuration of the compound as 4. R 6 S ,11 S ,13 S 15 S .

[0118] In summary, the structure of the new compound 2 (i.e., compound (-)-humulunone A) is determined as follows:

[0119] .

[0120] Example 2

[0121] This embodiment discloses a method for preparing a novel 5-6-7-5 cyclic β-acid compound, comprising the following steps:

[0122] S1. Take the dried aerial parts of hops, add solvent and reflux extract, combine the extracts and concentrate to obtain an extract; specifically, the solvent is an 88-98 V% aqueous ethanol solution; the mass of the solvent added is 8-10 times that of the hops, the reflux extraction is performed 1-3 times, and each extraction is performed for 1-3 hours.

[0123] The specific implementation plan is as follows: Weigh 208 kg of dried aerial parts of hops, add 10 times the mass of 95% ethanol aqueous solution as solvent and reflux extract three times, each extraction for 2 hours, combine the extracts and concentrate to obtain an extract (about 9.0 kg).

[0124] S2. After suspending the extract in water, extract it with dichloromethane to obtain the extract;

[0125] Further, in step S2, the extract is suspended in 8-15 times its weight of water and then extracted with dichloromethane.

[0126] The specific steps are as follows: After suspending the extract (9.0 kg) in 10 times its weight of water (90 L), extract it with 1.5 times its volume of dichloromethane. Extract three times to obtain dichloromethane extract (about 3100 g).

[0127] S3. The extract was subjected to gradient elution using a petroleum ether-ethyl acetate solution via silica gel column chromatography to obtain fraction C. When identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C was 0.55-0.62. Based on a total volume of 100, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when fraction C was eluted was (58:42)-(62:38); more preferably, the volume ratio was 60:40.

[0128] It should be noted that elution with a petroleum ether-ethyl acetate solution at a volume ratio of (58:42)–(62:38) and identification of fraction C with an Rf value of 0.55–0.62 using silica gel thin-layer chromatography were employed. The volume ratio of the petroleum ether-ethyl acetate solution required to obtain fraction C was between (58:42) and (62:38), with the highest efficiency achieved when eluting with a petroleum ether-ethyl acetate solution at a volume ratio of 60:40. The following gradient elution principles are essentially the same.

[0129] In this application, the Rf value is the Rf value of the fluorescent spot observed at scanning wavelengths of 254 nm and 365 nm.

[0130] The specific steps are as follows: The dichloromethane extract was subjected to silica gel column chromatography, using a petroleum ether-ethyl acetate gradient elution at volume ratios of 100:0, 80:20, 60:40, 30:70, and 0:100, with each 500 mL volume representing one fraction, yielding 35 fractions in total: 1-5, 6-10, 11-25, 26-29, and 30-35. These fractions were then identified using silica gel thin-layer chromatography, based on the values ​​at 254 nm and 365 nm. Fluorescent spots with Rf values ​​of 0.81-0.83 (fractions 1-5), 0.67-0.78 (fractions 6-10), 0.55-0.62 (fractions 11-25), 0.40-0.52 (fractions 26-29), and 0.32-0.38 (fractions 30-35) observed at nm were combined to obtain 5 fractions, named A, B, C, D, and E respectively; among them, fraction C was obtained by combining fractions 11-25.

[0131] The characteristic ultraviolet absorption (λ) of 5-7-5 ring β acids observed by HPLC analysis max = 274 nm) Select fraction C for the next separation step.

[0132] S4. Fraction C is eluted by gradient elution using a petroleum ether-ethyl acetate solution via silica gel column chromatography to obtain fraction C21. When identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C21 is 0.24-0.26. The volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when fraction C21 is eluted (i.e., the volume ratio corresponding to fraction C21) is (14:86)-(16:84), preferably 15:85.

[0133] The specific operating steps include: passing fraction C through silica gel column chromatography, using a petroleum ether-ethyl acetate gradient elution with volume ratios of 100:0, 95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, 50:50, 45:55, 40:60, 35:65, 30:70, 27:73, 25:75, 22:78, 20:80, 17:83, 15:85, 12:88, 10:90, 5:95, and 0:100 to sequentially obtain fraction 1- 4, 5-8, 9-14, 15-18, 19-23, 24-30, 31-34, 35-41, 42-49, 50-55, 56-64, 65-71, 72-75, 76-80, 81-90, 91-100, 101-105, 106-109, 110-115, 116-119, 120-124, 125-130, 131-135, 136-138, 139-142, a total of 142 fractions, were then identified using silica gel thin-layer chromatography, based on wavelengths of 254 nm and 365 nm. The Rf values ​​of the fluorescent spots observed at nm were 0.84-0.88 (fractions 1-4), 0.80-0.83 (fractions 5-8), 0.76-0.78 (fractions 9-14), 0.72-0.75 (fractions 15-18), 0.68-0.70 (fractions 19-23), 0.64-0.67 (fractions 24-30), and 0.61-0.63 (fractions 19-23). Fractions 31-34, 0.57-0.59 (fraction 35-41), 0.52-0.55 (fraction 42-49), 0.49-0.51 (fraction 50-55), 0.46-0.48 (fraction 56-64), 0.46-0.47 (fraction 65-71), 0.44-0.45 (fraction 72-75), 0.42-0.43 (fraction 76) -80), 0.39-0.41 (fraction 81-90), 0.37-0.38 (fraction 91-100), 0.35-0.36 (fraction 101-105), 0.33-0.34 (fraction 106-109), 0.30-0.32 (fraction 110-115), 0.27-0.29 (fraction 116-119), 0.24-0. Fractions 26 (120-124), 0.21-0.23 (125-130), 0.20-0.22 (131-135), 0.18-0.19 (136-138), and 0.15-0.17 (139-142) are combined to obtain fractions C1-C25; among them, fractions 120-124 are combined to form fraction C21.

[0134] S5. Using dichloromethane-methanol, fraction C21 is eluted isocratically by Sephadex LH-20 gel column chromatography to obtain fraction C21.2; when identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C21.2 is 0.70-0.75; the volume ratio of dichloromethane to methanol in the dichloromethane-methanol elution of fraction C21.2 (i.e., the fraction corresponding to C21.2) is (6:4)-(3:7), preferably 5:5.

[0135] Specific procedures include: analyzing the characteristic ultraviolet absorption (λ) of β-acids observed by HPLC. max = 274 nm) C21 was selected for further separation. Fraction C21 was subjected to Sephadex LH-20 gel column chromatography with isocratic elution using dichloromethane-methanol at a volume ratio of 5:5. A total of 35 fractions, 1-10, 11-15, 16-20, 21-25, and 26-35, were collected sequentially. Silica gel thin-layer chromatography was used for identification. Based on the Rf values ​​of the fluorescent spots observed at wavelengths of 254 nm and 365 nm, which were 0.77-0.82 (fractions 1-10), 0.70-0.75 (fractions 11-15), 0.62-0.69 (fractions 16-20), 0.53-0.59 (fractions 21-25), and 0.42-0.48 (fractions 26-35), respectively, five fractions were combined to obtain C21.1~C21.5. Among them, fractions 11-15 are combined to form fraction C21.2.

[0136] S6. The 5-6-7-5 ring β-acid compounds having structures as shown in formula (3) and / or (4) were separated from fraction C21.2 by HPLC.

[0137] The mobile phase used in the HPLC method is acetonitrile-water solution.

[0138] This application uses acetonitrile-water as the mobile phase and employs HPLC method, utilizing C 18 The chromatographic column was used to prepare 5-6-7-5 cyclic β-acid compounds with the structural formulas shown in formulas (3) and (4) in fraction C21.2.

[0139] Wherein, the volume ratio of acetonitrile to water in the acetonitrile-water solution is (45:55) to (50:50). Preferably, the volume ratio of acetonitrile to water in the acetonitrile-water solution is 48:52.

[0140] The characteristic ultraviolet absorption (λ) of 5-6-7-5 ring β acids observed by HPLC analysis max = 274 nm) Further separation of fraction C21.2 was performed, including 5-6-7-5 cyclic β-acid compounds with the structural formula as shown in formula (3) with a retention time of 42-45 min (purity: 98%).

[0141] In addition, the retention time of 5-6-7-5 ring β-acid compounds with the structural formula as shown in formula (4) is 47-50 min (purity: 98%).

[0142] The physical properties and detection data of compound 3 obtained in Example 2 are as follows:

[0143] A pale yellow, oily liquid, readily soluble in dichloromethane and methanol. High-resolution mass spectrometry (HR-ESI-MS) m / z 449.2534 ([M + H]) + The calculated value is 449.2495, suggesting the molecular formula of the compound is C. 25 H 36 O7 has an unsaturation degree of 8.

[0144] 1 1H NMR (CDCl3, 400 MHz) spectrum ( Figure 7 This indicates the presence of a hydrogen proton signal connected to an electron-withdrawing group in the low-field region. d H 4.58 (1H, t, J = 7.9 Hz, H-11); there are 3 sets of methylene proton signals in the high field region [ d H 2.16 (1H, dd, J = 7.2, 15.1 Hz, H-5), 2.81 (1H, dd, J = 9.5, 15.1 Hz, H-5), 3.28 (1H, dd, J =8.2, 13.8 Hz, H-12), 2.05 (1H, overlapped, H-12), 2.07 (1H, overlapped, H-14), 2.36 (1H, dd, J = 13.6, 10.9 Hz, H-14), 6 single-peak methyl proton signals [ d H 1.34, 1.29, 1.27, 1.23, 1.20, 1.14 (each 3H, s)], two bimodal methyl proton signals [ d H 1.11, 1.08 (each3H, d, J = 7.0 Hz, CH3-21, 22). The above information suggests that this compound may be a β-acid compound.

[0145] 13The C10 NMR (CDCl3, 100 MHz) spectrum showed a total of 25 carbon signals ( Figure 8 ), including 3 carbonyl carbon signals ( d C 205.8, 190.7, 170.0), a pair of olefin carbon signals ( d C 172.3, 114.7), 4 oxygen-carbon signals ( d C 94.6, 91.5, 73.3, 71.3), 3 sp 3 Hybridized methylene carbon signal ( d C 30.6, 30.2, 27.4), 8 methyl carbon signals ( d C The information above (31.0, 30.4, 27.3, 27.2, 25.2, 24.6, 18.3, 17.8) suggests that compound 3 may contain a furan ring synthesized from an isopentenyl and an enol hydroxyl ring, a 1-carbonyl isobutyl segment, two 2-hydroxyisopropyl segments, and a lactone ring.

[0146] 1 H NMR, 13 The signal assignments for C NMR are shown in Table 3.

[0147] Table 3 NMR data of compound 3 d (ppm)

[0148]

[0149] HMBC Map ( Figure 9 In ), H-5 ( d H 2.17) and C-6 ( d C 94.6), C-3 ( d C 73.3), C-4 ( d C 56.4), C-15 ( d C 50.3), C-16 ( d C The long-range correlation of 44.7) proves the connection between the five-membered and seven-membered rings at C-6 and C-15, and also proves the presence of a 2-hydroxyisopropyl fragment at position 4, which also indirectly confirms the presence of a pair of geminal dimethyl groups at position C-16; H-12 ( d H 3.30) and C-9 ( d C 172.3), C-13 ( d C The long-range correlation of 55.7 proves the connection between the five-membered furan ring and the seven-membered ring at C-9 and C-13, and this connection is also demonstrated through H-14 ( d H 2.36) and C-9 ( d C 172.3), C-12 ( d C 32.3), C-13 ( d C The long-range correlation of 50.3) is corroborated; H-12 ( d H 3.30) and C-11 ( d C 91.5), C-23 ( d C The correlation of 71.3) confirms the linkage of the 2-hydroxyisopropyl fragment at the C-11 position, H-12 ( d H 3.30) and H-14 ( d H The correlation between 2.36 and C-27 (170.0) further confirmed the connection of the lactone ring at C-6 and C-13. Long-range correlation of the high-field region 4 composition with the methyl proton signal confirmed the connection positions of the 1-carbonyl isobutyl segment, two 2-hydroxyisopropyl segments, and a set of geminal dimethyl segments. Based on the above information, the planar structure of compound 3 was deduced, suggesting it is a β-acid derivative. Comparison of calculated circular dichroism (ECD) data with measured ECD data confirmed the absolute configuration of the compound as 4. S 6 R ,11 R ,13 R 15 S .

[0150] In summary, the structure of the new compound 3 (compound (+)-humulunone B) was determined as follows:

[0151]

[0152] The physical properties and detection data of compound 4 obtained in Example 2 are as follows:

[0153] A pale yellow, oily liquid, readily soluble in dichloromethane and methanol. High-resolution mass spectrometry (HR-ESI-MS) m / z 449.2534 ([M + H]) + The calculated value is 449.2495, suggesting the molecular formula of the compound is C.25 H 36 O7 has an unsaturation degree of 8.

[0154] 1 1H NMR (CDCl3, 400 MHz) spectrum ( Figure 10 This indicates the presence of a hydrogen proton signal connected to an electron-withdrawing group in the low-field region. d H 4.58 (1H, t, J = 7.9 Hz, H-11); there are 3 sets of methylene proton signals in the high field region [ d H 2.16 (1H,dd, J = 7.2, 15.1 Hz, H-5), 2.81 (1H, dd, J = 9.5, 15.1 Hz, H-5), 3.30 (1H, dd, J =8.2, 13.8 Hz, H-12), 2.05 (1H, overlapped, H-12), 2.07 (1H, overlapped, H-14), 2.36 (1H, dd, J = 13.6, 10.9 Hz, H-14), 6 single-peak methyl proton signals [ d H 1.34, 1.29, 1.27, 1.23, 1.20, 1.14 (each 3H, s)], two bimodal methyl proton signals [ d H 1.11, 1.08 (each3H, d, J = 7.0 Hz, CH3-21, 22). The above information suggests that this compound may be a β-acid compound.

[0155] 13 The C10 NMR (CDCl3, 100 MHz) spectrum showed a total of 25 carbon signals ( Figure 11 ), including 3 carbonyl carbon signals ( d C 205.8, 190.7, 170.0), a pair of olefin carbon signals ( d C 172.3, 114.7), 4 oxygen-carbon signals ( d C 94.6, 91.5, 73.3, 71.3), 3 sp 3 Hybridized methylene carbon signal ( dC 30.6, 30.2, 27.4), 8 methyl carbon signals ( d C The information above (31.0, 30.4, 27.3, 27.2, 25.2, 24.6, 18.3, 17.8) suggests that compound 4 may contain a furan ring synthesized from an isopentenyl and an enol hydroxyl ring, a 1-carbonyl isobutyl segment, two 2-hydroxyisopropyl segments, and a lactone ring.

[0156] 1 H NMR, 13 The signal assignments for C NMR are shown in Table 4.

[0157] Table 4 NMR data of compound 4 d (ppm)

[0158]

[0159] HMBC Map ( Figure 12 In ), H-5 ( d H 2.17) and C-6 ( d C 94.6), C-3 ( d C 73.3), C-4 ( d C 56.4), C-15 ( d C 50.3), C-16 ( d C The long-range correlation of 44.7) proves the connection between the five-membered and seven-membered rings at C-6 and C-15, and also proves the presence of a 2-hydroxyisopropyl fragment at position 4, which also indirectly confirms the presence of a pair of geminal dimethyl groups at position C-16; H-12 ( d H 3.30) and C-9 ( d C 172.3), C-13 ( d C The long-range correlation of 55.7 proves the connection between the five-membered furan ring and the seven-membered ring at C-9 and C-13, and this connection is also demonstrated through H-14 ( d H 2.36) and C-9 ( d C 172.3), C-12 ( d C 32.3), C-13 ( d C The long-range correlation of 50.3) is corroborated; H-12 ( d H 3.30) and C-11 ( d C 91.5), C-23 ( d C The correlation of 71.3) confirms the linkage of the 2-hydroxyisopropyl fragment at the C-11 position, H-12 ( d H 3.30) and H-14 ( d H The correlation between 2.36 and C-27 (170.0) further confirmed the connection of the lactone ring at C-6 and C-13. Long-range correlation of the high-field region 4 composition with the methyl proton signal confirmed the connection positions of the 1-carbonyl isobutyl segment, two 2-hydroxyisopropyl segments, and a set of geminal dimethyl segments. Based on the above information, the planar structure of compound 4 was deduced, suggesting it is a β-acid derivative. Comparison of calculated circular dichroism (ECD) data with measured ECD data confirmed the absolute configuration of the compound as 4. R 6 S ,11 S ,13 S 15 R .

[0160] In summary, the structure of the new compound 4 (compound (-)-humulunone B) was determined as follows:

[0161] .

[0162] Example 3

[0163] This embodiment discloses a method for preparing a novel 5-6-7-5 cyclic β-acid compound, comprising the following steps:

[0164] S1. Take the dried aerial parts of hops, add solvent and reflux extract, combine the extracts and concentrate to obtain an extract; specifically, the solvent is an 88-98 V% aqueous ethanol solution; the mass of the solvent added is 8-10 times that of the hops, the reflux extraction is performed 1-3 times, and each extraction is performed for 1-3 hours.

[0165] The specific implementation plan is as follows: Weigh 208 kg of dried aerial parts of hops, add 10 times the mass of 95% ethanol aqueous solution as solvent and reflux extract three times, each extraction for 2 hours, combine the extracts and concentrate to obtain an extract (about 9.0 kg).

[0166] S2. After suspending the extract in water, extract it with dichloromethane to obtain the extract;

[0167] Further, in step S2, the extract is suspended in 8-15 times its weight of water and then extracted with dichloromethane.

[0168] The specific steps are as follows: After suspending the extract (9.0 kg) in 10 times its weight of water (90 L), extract it with 1.5 times its volume of dichloromethane. Extract three times to obtain dichloromethane extract (about 3100 g).

[0169] S3. The extract was subjected to gradient elution using a petroleum ether-ethyl acetate solution via silica gel column chromatography to obtain fraction C. When identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C was 0.55-0.62. Based on a total volume of 100, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when fraction C was eluted was (58:42)-(62:38); more preferably, the volume ratio was 60:40.

[0170] It should be noted that elution with a petroleum ether-ethyl acetate solution at a volume ratio of (58:42)–(62:38) and identification of fraction C with an Rf value of 0.55–0.62 using silica gel thin-layer chromatography were employed. The volume ratio of the petroleum ether-ethyl acetate solution required to obtain fraction C was between (58:42) and (62:38), with the highest efficiency achieved when eluting with a petroleum ether-ethyl acetate solution at a volume ratio of 60:40. The following gradient elution principles are essentially the same.

[0171] In this application, the Rf value is the Rf value of the fluorescent spot observed at scanning wavelengths of 254 nm and 365 nm.

[0172] The specific steps are as follows: The dichloromethane extract was subjected to silica gel column chromatography, using a petroleum ether-ethyl acetate gradient elution at volume ratios of 100:0, 90:10, 80:20, 60:40, 50:50, 40:60, 30:70, 20:80, 10:90, and 0:100, with each 500 mL volume representing one fraction. Thirty-five fractions were obtained sequentially: 1-5, 6-10, 11-25, 26-29, and 30-35. These fractions were identified using silica gel thin-layer chromatography, based on 254 nm and 365 nm. Fluorescent spots with Rf values ​​of 0.81-0.83 (fractions 1-5), 0.78-0.80 (fractions 6-10), 0.75-0.77 (fractions 11-25), 0.72-0.74 (fractions 26-29), and 0.65-0.68 (fractions 30-35) observed at nm were combined to obtain five fractions, named A, B, C, D, and E respectively; among them, fraction C was obtained by combining fractions 11-25.

[0173] The characteristic ultraviolet absorption (λ) of the 5-6-7-5 ring β-acid was observed based on HPLC analysis. max = 274 nm) Select fraction C for the next separation step.

[0174] S4. Fraction C is eluted by gradient elution using a petroleum ether-ethyl acetate solution via silica gel column chromatography to obtain fraction C20. When identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C20 is 0.27-0.29. The volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when fraction C20 is eluted (i.e., the volume ratio corresponding to fraction C20) is (16:84)-(19:81), preferably 17:83.

[0175] The specific operating steps include: passing fraction C through silica gel column chromatography, using a petroleum ether-ethyl acetate gradient elution with volume ratios of 100:0, 95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, 50:50, 45:55, 40:60, 35:65, 30:70, 27:73, 25:75, 22:78, 20:80, 17:83, 15:85, 12:88, 10:90, 5:95, and 0:100 to sequentially obtain fraction 1- 4, 5-8, 9-14, 15-18, 19-23, 24-30, 31-34, 35-41, 42-49, 50-55, 56-64, 65-71, 72-75, 76-80, 81-90, 91-100, 101-105, 106-109, 110-115, 116-119, 120-124, 125-130, 131-135, 136-138, 139-142, a total of 142 fractions, were then identified using silica gel thin-layer chromatography, based on wavelengths of 254 nm and 365 nm. The Rf values ​​of the fluorescent spots observed at nm were 0.84-0.88 (fractions 1-4), 0.80-0.83 (fractions 5-8), 0.76-0.78 (fractions 9-14), 0.72-0.75 (fractions 15-18), 0.68-0.70 (fractions 19-23), 0.64-0.67 (fractions 24-30), and 0.61-0.63 (fractions 19-23). Fractions 31-34, 0.57-0.59 (fraction 35-41), 0.52-0.55 (fraction 42-49), 0.49-0.51 (fraction 50-55), 0.46-0.48 (fraction 56-64), 0.46-0.47 (fraction 65-71), 0.44-0.45 (fraction 72-75), 0.42-0.43 (fraction 76) -80), 0.39-0.41 (fraction 81-90), 0.37-0.38 (fraction 91-100), 0.35-0.36 (fraction 101-105), 0.33-0.34 (fraction 106-109), 0.30-0.32 (fraction 110-115), 0.27-0.29 (fraction 116-119), 0.24-0. Fractions 26 (120-124), 0.21-0.23 (125-130), 0.20-0.22 (131-135), 0.18-0.19 (136-138), and 0.15-0.17 (139-142) are combined to obtain fractions C1-C25; among them, fractions 116-119 are combined to form fraction C20.

[0176] S5. Using a petroleum ether-ethyl acetate solution, fraction C20 is eluted by gradient elution using silica gel column chromatography to obtain fraction C20.9. When identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C20.9 is 0.43-0.45. The volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution eluted from fraction C20.9 (i.e., the fraction corresponding to C20.9) is (35:65)-(45:55), preferably 40:60.

[0177] Specific procedures include: analyzing the characteristic ultraviolet absorption (λ) of β-acids observed by HPLC. max = 274 nm) C20 was selected for further separation. Fraction C20 was subjected to silica gel column chromatography using a petroleum ether-ethyl acetate gradient elution at volume ratios of 100:0, 95:5, 90:10, 85:15, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80, and 0:100. Sixty fractions (1-5, 6-10, 11-15, 16-20, 21-25, 26-31, 32-35, 36-41, 42-46, 47-51, 52-55, and 56-60) were collected sequentially and identified by silica gel thin-layer chromatography at wavelengths of 254 nm and 365 nm. The Rf values ​​of the fluorescent spots observed at nm were 0.83-0.85 (fractions 1-5), 0.79-0.82 (fractions 6-10), 0.75-0.78 (fractions 11-15), 0.71-0.73 (fractions 16-20), 0.67-0.69 (fractions 21-25), 0.63-0.66 (fractions 26-31), 0.54-0.62 (fractions 32-35), 0.47-0.50 (fractions 36-41), 0.43-0.45 (fractions 42-46), 0.36-0.40 (fractions 47-51), 0.31-0.34 (fractions 52-55), and 0.26-0.29 (fractions 56-60). These values ​​were combined to obtain 12 fractions, C20.1-C20.12. Among them, fractions 42-46 are combined to form fraction C20.9.

[0178] S6. Fraction C20.9 was isocratically eluted with methanol using Sephadex LH-20 gel column chromatography to obtain fraction C20.9.1. When identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C20.9.1 was 0.77-0.82.

[0179] The specific procedures include: analyzing the characteristic ultraviolet absorption (λ) observed by HPLC. max= 274 nm) C20.9 was selected for further separation. Fraction C20.9 was subjected to Sephadex LH-20 gel column chromatography with isocratic elution using pure methanol, and 35 fractions (1-10, 11-15, 16-20, 21-25, 26-35) were collected sequentially. Silica gel thin-layer chromatography was used for identification. Based on the Rf values ​​of the fluorescent spots observed at wavelengths of 254 nm and 365 nm, which were 0.77-0.82 (fractions 1-10), 0.70-0.75 (fractions 11-15), 0.62-0.69 (fractions 16-20), 0.53-0.59 (fractions 21-25), and 0.42-0.48 (fractions 26-35), respectively, five fractions were combined to obtain C20.9.1~C20.9.5. Among them, fractions 1-10 are combined to form fraction C20.9.1.

[0180] S7. The 5-6-7-5 ring β-acid compounds having structures as shown in formula (5) and / or (6) were separated from fraction C20.9.1 by HPLC.

[0181] The mobile phase used in the HPLC method is acetonitrile-water solution.

[0182] This application uses acetonitrile-water as the mobile phase and employs HPLC method, utilizing C 18 The chromatographic column was used to prepare 5-6-7-5 cyclic β-acid compounds with the structural formulas shown in formulas (5) and (6) in fraction C20.9.1.

[0183] Wherein, the volume ratio of acetonitrile to water in the acetonitrile-water solution is (43:57) to (48:52). Preferably, the volume ratio of acetonitrile to water in the acetonitrile-water solution is 45:55.

[0184] The characteristic ultraviolet absorption (λ) of β-acids observed by HPLC analysis max = 274 nm) Further separation of fraction C20.9.1 was performed, including 5-6-7-5 cyclic β-acid compounds with the structural formula as shown in formula (5) with a retention time of 45-48 min (purity: 98%).

[0185] In addition, the retention time of 5-6-7-5 ring β-acid compounds with the structural formula as shown in formula (6) is 51-53 min (purity: 98%).

[0186] The physical properties and detection data of compound 5 obtained in Example 3 are as follows:

[0187] Pale yellow powder; based on high-resolution mass spectrometry (HR-ESI-MS). m / z 463.2692 ([M + H]) +The calculated value is 463.2696, suggesting the molecular formula of the compound is C. 26 H 38 O7 has an unsaturation degree of 8.

[0188] 1 1H NMR (CDCl3, 400 MHz) spectrum Figure 13 This indicates the presence of a hydrogen proton signal connected to an electron-withdrawing group in the low-field region. d H 4.59 (1H, dd, J = 8.5, 7.4 Hz, H-11); 4 sets of methylene proton signals were observed in the high-field region. d H 3.30(1H, dd, J = 13.7, 8.5 Hz, H-12), 2.04 (1H, dd, J = 9.0, 7.2 Hz, H-12), 2.06 (1H,dd, J = 8.9, 7.0 Hz, H-14), 2.35 (1H, dd, J = 13.6, 11.0 Hz, H-14),2.17 (1H, dd, J = 15.1, 7.2 Hz, H-5), 2.80 (1H, dd, J = 15.1, 9.8 Hz, H-5), 2.54 (1H, d, J = 6.9Hz, H-20), 6 single-peak methyl proton signals [ d H 1.34, 1.30, 1.29, 1.24, 1.20, 1.14 (each 3H, s)], two bimodal methyl proton signals [ d H 0.92, 0.92 (each 3H, J = 6.7 Hz, CH3-22, 23).

[0189] 13 C10 NMR (CDCl3, 100 MHz) spectrum Figure 14 The display shows a total of 26 carbon signals, including 3 carbonyl carbon signals. d C 201.4, 190.5, 169.8), a pair of olefin carbon signals ( d C 172.4, 115.5), 4 oxygen-carbon signals ( dC 94.5, 91.6, 73.2, 71.3), 4 sp 3 Hybridized methylene carbon signal ( d C 53.0, 33.9, 32.3, 30.5), 8 methyl carbon signals ( d C 31.0, 30.4, 28.6, 27.5, 26.2, 25.1, 22.8, 22.7)

[0190] 1 H NMR, 13 The signal assignments for C NMR are shown in Table 5.

[0191] Table 5 NMR data for compound 5 d (ppm)

[0192]

[0193] In the HMBC map ( Figure 15 In ), H-5 ( d H 2.80) and C-6 ( d C 94.5), C-3 ( d C 73.2), C-4 ( d C 56.3), C-15 ( d C 50.3), C-16 ( d C The long-range correlation of 44.6) proves the connection between the five-membered ring and the seven-membered ring at C-6 and C-15, and also proves the existence of a 2-hydroxyisopropyl fragment at position 4, which also indirectly confirms the presence of a pair of geminal dimethyl groups at position C-16; H-12 ( d H 3.30) and C-9 ( d C 172.4), C-13 ( d C The long-range correlation of 55.8 proves the connection between the five-membered furan ring and the seven-membered ring at C-9 and C-13, and this connection is also demonstrated through H-14 ( d H 2.35) and C-9 ( d C 172.4), C-12 ( d C 32.3), C-13 ( d CThe long-range correlation of H-12 (55.8) is corroborated; d H 3.30) and C-11 ( d C 91.6), C-24 ( d C The correlation of 71.3) confirms the linkage of the 2-hydroxyisopropyl fragment at the C-11 position, H-12 ( d H 3.30) and H-14 ( d H The correlation between 2.35 and C-27 (169.8) further confirmed the connection of the lactone ring at C-6 and C-13. Long-range correlation of the high-field region 4 composition with the methyl proton signal confirmed the connection positions of the 1-carbonyl isobutyl segment, two 2-hydroxyisopropyl segments, and a set of gem-dimethyl groups. Comparison of calculated circular dichroism (ECD) data with measured ECD data confirmed the absolute configuration of the compound as 4. S 6 R ,11 R ,13 R 15 S .

[0194] In summary, the structure of the new compound 5 (i.e., compound (+)-humulunone C) was determined as follows:

[0195]

[0196] The physical properties and detection data of compound 6 obtained in Example 3 are as follows:

[0197] Pale yellow powder; based on high-resolution mass spectrometry (HR-ESI-MS). m / z 463.2691 ([M + H]) + The calculated value is 463.2696, suggesting the molecular formula of the compound is C. 26 H 38 O7 has an unsaturation degree of 8.

[0198] 1 1H NMR (CDCl3, 400 MHz) spectrum Figure 16 This indicates the presence of a hydrogen proton signal connected to an electron-withdrawing group in the low-field region. d H 4.59 (1H, dd, J = 8.5, 7.4 Hz, H-11); 4 sets of methylene proton signals were observed in the high-field region. d H 3.30(1H, dd, J= 13.7, 8.5 Hz, H-12), 2.04 (1H, dd, J = 9.0, 7.2 Hz, H-12), 2.06 (1H,dd, J = 8.9, 7.0 Hz, H-14), 2.35 (1H, dd, J = 13.6, 11.0 Hz, H-14),2.17 (1H, dd, J = 15.1, 7.2 Hz, H-5), 2.80 (1H, dd, J = 15.1, 9.8 Hz, H-5), 2.54 (1H, d, J = 6.9Hz, H-20), 6 single-peak methyl proton signals [ d H 1.34, 1.30, 1.29, 1.24, 1.20, 1.14 (each 3H, s)], two bimodal methyl proton signals [ d H 0.92, 0.92 (each 3H, J = 6.7 Hz, CH3-22, 23).

[0199] 13 C10 NMR (CDCl3, 100 MHz) spectrum Figure 17 The display shows a total of 26 carbon signals, including 3 carbonyl carbon signals. d C 201.4, 190.5, 169.8), a pair of olefin carbon signals ( d C 172.4, 115.5), 4 oxygen-carbon signals ( d C 94.5, 91.6, 73.2, 71.3), 4 sp 3 Hybridized methylene carbon signal ( d C 53.0, 33.9, 32.3, 30.5), 8 methyl carbon signals ( d C 31.0, 30.4, 28.6, 27.5, 26.2, 25.1, 22.8, 22.7)

[0200] 1 H NMR, 13 The signal assignments for C NMR are shown in Table 6.

[0201] Table 6 NMR data of compound 6 d (ppm)

[0202]

[0203] In the HMBC map ( Figure 18 In ), H-5 ( d H 2.80) and C-6 ( d C 94.5), C-3 ( d C 73.2), C-4 ( d C 56.3), C-15 ( d C 50.3), C-16 ( d C The long-range correlation of 44.6) proves the connection between the five-membered ring and the seven-membered ring at C-6 and C-15, and also proves the existence of a 2-hydroxyisopropyl fragment at position 4, which also indirectly confirms the presence of a pair of geminal dimethyl groups at position C-16; H-12 ( d H 3.30) and C-9 ( d C 172.4), C-13 ( d C The long-range correlation of 55.8 proves the connection between the five-membered furan ring and the seven-membered ring at C-9 and C-13, and this connection is also demonstrated through H-14 ( d H 2.35) and C-9 ( d C 172.4), C-12 ( d C 32.3), C-13 ( d C The long-range correlation of H-12 (55.8) is corroborated; d H 3.30) and C-11 ( d C 91.6), C-24 ( d C The correlation of 71.3) confirms the linkage of the 2-hydroxyisopropyl fragment at the C-11 position, H-12 ( d H 3.30) and H-14 ( d HThe correlation between 2.35 and C-27 (169.8) further confirmed the connection of the lactone ring at C-6 and C-13. Long-range correlation of the high-field region 4 composition with the methyl proton signal confirmed the connection positions of the 1-carbonyl isobutyl segment, two 2-hydroxyisopropyl segments, and a set of gem-dimethyl groups. Comparison of calculated circular dichroism (ECD) data with measured ECD data confirmed the absolute configuration of the compound as 4. R 6 S ,11 S ,13 S 15 R .

[0204] In summary, the structure of the new compound 6 (i.e., compound (-)-humulunone C) was determined as follows:

[0205]

[0206] Comparative Example 1

[0207] Comparative Example 1 of the present invention provides a method for preparing a novel 5-6-7-5 cyclic β-acid compound. The steps are similar to those in Example 1, except that in step S5, when the fraction C20 is subjected to silica gel column chromatography, petroleum ether-ethyl acetate with a volume ratio of less than 35:65 or greater than 45:55 is used for elution.

[0208] The results showed that compounds 1 and 2 could not be prepared.

[0209] Comparative Example 2

[0210] Comparative Example 2 of the present invention provides a method for preparing a novel 5-6-7-5 cyclic β-acid compound. The steps are similar to those in Example 2, except that in step S5, when fraction C21 is subjected to gel column chromatography, dichloromethane-methanol with a volume ratio of less than 3:7 or more than 6:4 is used for elution.

[0211] The results showed that compounds 3 and 4 could not be prepared.

[0212] Comparative Example 3

[0213] Comparative Example 3 of the present invention provides a method for preparing a novel 5-6-7-5 cyclic β-acid compound. The steps are similar to those in Example 3, except that in step S7, the volume ratio of acetonitrile to water in the mobile phase used for separating fraction C20.9.1 by HPLC is lower than 43:57 or higher than 48:52.

[0214] The results showed that compounds 5 and 6 could not be prepared.

[0215] To better understand the essence of this invention, the following describes the new applications of the above-mentioned 5-7-5 cyclic β-acid compounds in the pharmaceutical field, in conjunction with pharmacological tests and results.

[0216] Experimental Example 1

[0217] This experimental example discloses the NO-inhibiting activity of the above-mentioned compound (±)-Humulunones AC.

[0218] (1) Experimental materials and instruments

[0219] BV2 cell line was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai).

[0220] RPMI 1640 medium (Beijing Solarbio Science & Technology Co., Ltd.);

[0221] PBS buffer (Gibco, USA);

[0222] Fetal bovine serum (FBS, Gibco, USA);

[0223] Trypsin (Gibco, USA);

[0224] NO detection kit (Beyotime, USA);

[0225] Dexamethasone (Shanghai Maclean Biotechnology Co., Ltd.);

[0226] Physiological saline (Beijing Pulizhicheng Biotechnology Co., Ltd.);

[0227] 96-well plate (Corning Corporation, USA);

[0228] (±)-Humulunones AC (made in the laboratory);

[0229] Carbon dioxide cell incubator (Thermo Scientific, USA);

[0230] Full-wavelength microplate reader (Thermo Scientific, USA);

[0231] BIOFUGE STRATOS centrifuge (Thermo Fisher Scientific, USA);

[0232] IX73 inverted electron microscope (Olympus Corporation, Japan);

[0233] Pipettes (Eppendorf, Germany);

[0234] Clean benches, centrifuge tubes, straws and other related consumables.

[0235] (2) Experimental methods

[0236] Cell resuscitation and culture: Remove the labeled BV2 cell cryovials from liquid nitrogen and immediately place them in a 37 ℃ water bath to thaw rapidly within 1 min. After disinfecting the cryovials with alcohol, transfer the cryopreservation solution into a 15 mL sterile centrifuge tube, add the appropriate culture medium, mix well, and centrifuge at 1000 rpm for 5 min to remove the supernatant. Repeat the above steps once for washing, then add 10 mL of culture medium, mix well, resuspend the cells, transfer them to a 10 mL culture dish, and incubate in a 37 ℃, 5% CO2 incubator.

[0237] Cell passage: When the cell density reaches 70%-80%, passage the cells. First, remove the old culture medium, wash twice with PBS, add trypsin containing EDTA to the culture dish and incubate at 37 ℃ for 3 min. Then, add culture medium to stop digestion, centrifuge at 1000 rpm for 5 min, remove the digestion solution, add serum-containing culture medium again and repeatedly pipette the cells to form a cell suspension. Finally, according to the number of cells, transfer them to a new culture dish to complete cell passage.

[0238] BV2 cells were seeded at a rate of 2 × 10⁴ cells / well in 96-well plates, with 6 replicates per group. After seeding, the cells were cultured for 24 hours. Lipopolysaccharide was added to the model group and each drug-treated group for induction. The positive control drug dexamethasone and compound (±)-Humulunones AC were dissolved and diluted to 10 μM and administered to the cells respectively. After treating the cells with 10 μL / well, the cells were incubated at 37 °C for 48 h. Then, 10 μL of the NO detection kit was added. After 2 h, the absorbance at 540 nm was measured using a microplate reader, and the amount of NO released was inhibited was calculated.

[0239] (3) Experimental results

[0240] As shown in Table 7, (+)-Humulunone A, (-)-Humulunone A, (+)-Humulunone B, (-)-Humulunone B, (+)-Humulunone C and (-)-Humulunone C inhibited lipopolysaccharide-induced NO release in BV2 cells, exhibiting significant anti-neuroinflammatory activity comparable to the positive control drug dexamethasone.

[0241] Table 7. Inhibitory activity of compounds on NO release in lipopolysaccharide-induced RAW 264.7 cells.

[0242]

[0243] Note: Compared with the blank group: ###P <0.001: Compared with the model group: *** P <0.001

[0244] Experimental Example 2

[0245] This experimental example discloses the inhibitory activity of the above-mentioned compound (±)-Humulunones AC on inflammatory factors.

[0246] (1) Experimental materials and instruments

[0247] BV2 cell line was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai).

[0248] RPMI 1640 medium (Beijing Solarbio Science & Technology Co., Ltd.);

[0249] PBS buffer (Gibco, USA);

[0250] Fetal bovine serum (FBS, Gibco, USA);

[0251] Trypsin (Gibco, USA);

[0252] ELISA test kit (Beyotime, USA);

[0253] Aspirin (Shanghai Maclean Biochemical Technology Co., Ltd.);

[0254] Physiological saline (Beijing Pulizhicheng Biotechnology Co., Ltd.);

[0255] 96-well plate (Corning Corporation, USA);

[0256] (±)-Humulunones AC (made in the laboratory);

[0257] Carbon dioxide cell incubator (Thermo Scientific, USA);

[0258] Full-wavelength microplate reader (Thermo Scientific, USA);

[0259] BIOFUGE STRATOS centrifuge (Thermo Fisher Scientific, USA);

[0260] IX73 inverted electron microscope (Olympus Corporation, Japan);

[0261] Pipettes (Eppendorf, Germany);

[0262] Clean benches, centrifuge tubes, straws and other related consumables.

[0263] (2) Experimental methods

[0264] Cell resuscitation and culture: Remove the labeled BV2 cell cryovials from liquid nitrogen and immediately place them in a 37 ℃ water bath to thaw rapidly within 1 min. After disinfecting the cryovials with alcohol, transfer the cryopreservation solution into a 15 mL sterile centrifuge tube, add the appropriate culture medium, mix well, and centrifuge at 1000 rpm for 5 min to remove the supernatant. Repeat the above steps once for washing, then add 10 mL of culture medium, mix well, resuspend the cells, transfer them to a 10 mL culture dish, and incubate in a 37 ℃, 5% CO2 incubator.

[0265] Cell passage: When the cell density reaches 70%-80%, passage the cells. First, remove the old culture medium, wash twice with PBS, add trypsin containing EDTA to the culture dish and incubate at 37 ℃ for 3 min. Then, add culture medium to stop digestion, centrifuge at 1000 rpm for 5 min, remove the digestion solution, add serum-containing culture medium again and repeatedly pipette the cells to form a cell suspension. Finally, according to the number of cells, transfer them to a new culture dish to complete cell passage.

[0266] BV2 cells were seeded at a rate of 2 × 10⁴ cells / well in 96-well plates, with 6 replicates per group. After seeding, the cells were cultured for 24 hours. Lipopolysaccharide was added to the model group and each drug-treated group for induction. The positive control drug aspirin and compound (±)-Humulunones AC were dissolved and diluted to 10 μM and administered to the cells respectively. After treatment with 10 μL / well, the cells were incubated at 37 °C for 48 h. The absorbance at 450 nm was measured using an ELISA kit, and the contents of TNF-α, IL-18, and IL-1β were calculated.

[0267] (3) Experimental results

[0268] As shown in Table 8, (±)-Humulunones AC inhibited the levels of inflammatory factors TNF-α, IL-18 and IL-1β in BV2 cells induced by lipopolysaccharide, exhibiting significant anti-neuroinflammatory activity, which was superior to the positive control drug aspirin.

[0269] Table 8. Inhibitory activity of compounds against lipopolysaccharide-induced inflammatory factors in RAW 264.7 cells.

[0270]

[0271] In summary, the novel 5-6-7-5 cyclic β-acid compounds (+)-Humulunone A, (-)-Humulunone A, (+)-Humulunone B, (-)-Humulunone B, (+)-Humulunone C, and (-)-Humulunone C described in this invention exhibit significant anti-neuroinflammatory activity, comparable to that of dexamethasone, a first-line clinical drug. They can be used as drugs to treat neuroinflammatory-related diseases, including but not limited to depression, Alzheimer's disease, Parkinson's syndrome, Huntington's disease, neuromyelitis optica, and peripheral neuritis.

[0272] Application Example 1

[0273] This invention discloses a capsule formulation using (+)-Humulunone A as the active pharmaceutical ingredient, the components of which are as follows:

[0274] (+)-Humulunone A 20.0 mg

[0275] Starch 5.0 g

[0276] Sodium metabisulfite 0.3 g

[0277] Magnesium stearate 0.3 g

[0278] Anhydrous ethanol appropriate amount

[0279] Make 100 pills.

[0280] The specific preparation process is as follows:

[0281] Take (+)-Humulunone A, starch, and sodium metabisulfite and mix them evenly. Add anhydrous ethanol to make a soft material, pass it through a 24-mesh sieve, make it into granules, dry it, add magnesium stearate, mix it evenly, and fill it into capsules.

[0282] Application Example 2

[0283] This invention discloses a granule formulation using compound (-)-Humulunone A as the active pharmaceutical ingredient, the components of which are as follows:

[0284] (-)-Humulunone A 20.0 mg

[0285] Starch 5.0 g

[0286] Sodium bisulfite 0.3 g

[0287] Magnesium stearate 0.3 g

[0288] Anhydrous ethanol appropriate amount

[0289] Make 100 bags.

[0290] The specific preparation process is as follows:

[0291] Take (-)-Humulunone A, mix it with starch and sodium bisulfite, add anhydrous ethanol to make a soft material, pass it through a 24-mesh sieve to make granules, dry it, add magnesium stearate, mix well, and pack it into bags.

[0292] Application Example 3

[0293] This invention discloses an oral liquid using compound (+)-Humulunone B as the active pharmaceutical ingredient, the components of which are as follows:

[0294] (+)-Humulunone B2 0.0 mg

[0295] 5.0 g sucrose

[0296] Sodium bisulfite 0.3 g

[0297] Methylparaben 0.3 g

[0298] Sodium bicarbonate 0.1 g

[0299] 1000 mL of water for injection

[0300] Make 100 pieces.

[0301] The specific preparation process is as follows:

[0302] After the above components are mixed, they can be dispensed using conventional oral liquid preparation methods.

[0303] Application Example 4

[0304] This invention discloses an injectable formulation using compound (+)-Humulunone B as the active pharmaceutical ingredient, the components of which are as follows:

[0305] (+)-Humulunone B2 0.0 mg

[0306] Vitamin C 0.2 g

[0307] Sodium chloride 6.0 g

[0308] Sodium bicarbonate 0.1 g

[0309] 1000 mL of water for injection

[0310] Make 100 pieces.

[0311] The specific preparation process is as follows:

[0312] After the above components are mixed, 100 vials can be obtained by using conventional injection preparation methods.

[0313] Application Example 5

[0314] This invention discloses a tablet using compound (-)-Humulunone B and aspirin as active pharmaceutical ingredients, the composition of which is as follows:

[0315] (-)-Humulunone B15.0 mg

[0316] Aspirin 2.5 g

[0317] 15 g of hydroxypropyl methylcellulose

[0318] 0.4 g talc

[0319] Lactose 0.2 g

[0320] Magnesium stearate 0.2 g

[0321] Anhydrous ethanol appropriate amount

[0322] Make 100 pieces.

[0323] The specific preparation process is as follows:

[0324] Mix (-)-Humulunone B, aspirin, hydroxypropyl methylcellulose, talc, lactose, and magnesium stearate evenly, add anhydrous ethanol to make a soft mass, pass it through a 24-mesh sieve to make granules, dry it, add magnesium stearate, mix well, and compress into tablets.

[0325] Application Example 6

[0326] This invention discloses a capsule formulation using compound (-)-Humulunone C and dexamethasone as active pharmaceutical ingredients, the components of which are as follows:

[0327] (-)-Humulunone C15.0 mg

[0328] Dexamethasone 0.3 g

[0329] Starch 6.0 g

[0330] Sodium metabisulfite 0.2 g

[0331] Magnesium stearate 0.2 g

[0332] Anhydrous ethanol appropriate amount

[0333] Make 100 pills.

[0334] The specific preparation process is as follows:

[0335] Take (-)-Humulunone B, ibuprofen, starch, and sodium metabisulfite, mix them, add anhydrous ethanol to make a soft material, pass it through a 24-mesh sieve to make granules, dry it, add magnesium stearate, mix it, and fill it into capsules.

[0336] Application Example 7

[0337] This invention discloses an injection formulation using compound (+)-Humulunone C and cortisone as active pharmaceutical ingredients, the components of which are as follows:

[0338] (+)-Humulunone C15.0 mg

[0339] Cortisone 20.0 mg

[0340] Vitamin C 0.2 g

[0341] Sodium chloride 6.0 g

[0342] Sodium bicarbonate 0.1 g

[0343] 1000 mL of water for injection

[0344] Make 100 pieces.

[0345] The specific preparation process is as follows:

[0346] After the above components are mixed, 100 vials can be obtained by using conventional injection preparation methods.

[0347] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the technical principles of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

[0348] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A 5-6-7-5 ring system β-acid compound or a salt thereof, characterized by, It has a structure shown in one of the following formulas (1)-(6): 。 2. A process for the preparation of a compound as claimed in claim 1, characterized in that, Includes the following steps: S1. Take the dried aerial parts of hops, add solvent and reflux to extract, combine the extracts and concentrate to obtain an extract, wherein the solvent is an 88-98 V% aqueous ethanol solution; S2. After suspending the extract in water, extract it with dichloromethane to obtain the extract; S3. The dichloromethane extract was subjected to gradient elution using a petroleum ether-ethyl acetate solution via silica gel column chromatography to obtain fraction AE. S4. Fraction C was subjected to gradient elution using petroleum ether-ethyl acetate solution via silica gel column chromatography to obtain fractions C20 and C21, respectively. When identified by silica gel thin-layer chromatography, the Rf value for fraction C20 was 0.27-0.29, and the Rf value for fraction C21 was 0.24-0.

26. S5. Fraction C20 was subjected to gradient elution using petroleum ether-ethyl acetate solution via silica gel column chromatography to obtain fraction C20.9; when identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C20.9 was 0.43-0.

45. S6. Fraction C21 was isocratically eluted using Sephadex LH-20 gel column chromatography with dichloromethane-methanol to obtain fraction C21.2; fraction C20.9 was isocratically eluted using Sephadex LH-20 gel column chromatography with methanol to obtain fractions C20.9.1 and C20.9.2; when identified by silica gel thin-layer chromatography, the Rf value corresponding to fraction C20.9.1 was 0.55-0.60, the Rf value corresponding to fraction C20.9.2 was 0.56-0.59, and the Rf value corresponding to fraction C21.2 was 0.70-0.75; S7. The 5-6-7-5 ring β-acid compounds with structures as shown in formula (1) and formula (2) were separated from fraction C20.9.2 by HPLC. The mobile phase used in the HPLC method is acetonitrile-water solution; S8. The 5-6-7-5 ring β-acid compounds having the structures shown in formula (3) and formula (4) were separated from fraction C21.2 by HPLC. The mobile phase used in the HPLC method is acetonitrile-water solution; S9. The 5-6-7-5 ring β-acid compounds having the structures shown in formulas (5) and (6) were separated from fraction C20.9.1 by HPLC. The mobile phase used in the HPLC method is acetonitrile-water solution.

3. The production method according to claim 2, characterized by, In step S7, the volume ratio of acetonitrile to water in the acetonitrile-water solution is (46:54)-(52:48).

4. The preparation method according to claim 2, characterized in that, In step S7, fraction C20.9.2 is further separated based on the characteristic ultraviolet absorption of 5-6-7-5 cyclic β-acids observed by HPLC analysis, including 5-6-7-5 cyclic β-acid compounds with the structural formula as shown in formula (1) having a retention time of 38-40 min; The retention time of 5-6-7-5 ring β-acid compounds, including those with the structural formula shown in formula (2), is 43-45 min.

5. The preparation method according to claim 2, characterized in that, In step S8, the volume ratio of acetonitrile to water in the acetonitrile-water solution is (45:55) to (50:50).

6. The preparation method according to claim 2, characterized in that, In step S8, fraction C21.2 is further separated based on the characteristic ultraviolet absorption of β-acids observed by HPLC analysis, including 5-6-7-5 ring β-acid compounds with the structural formula as shown in formula (3) with a retention time of 42-45 min; The retention time of 5-6-7-5 ring β-acid compounds, including those with the structural formula shown in formula (4), is 47-50 min.

7. The preparation method according to claim 2, characterized in that, In step S9, the volume ratio of acetonitrile to water in the acetonitrile-water solution is (43:57)-(48:52).

8. The preparation method according to claim 2, characterized in that, In step S8, fraction C20.9.1 is further separated based on the characteristic ultraviolet absorption of the 5-6-7-5 cyclic β-acid observed by HPLC analysis, and the retention time of the 5-6-7-5 cyclic β-acid compound with the structural formula as shown in formula (5) is 45-48 min. The retention time of 5-6-7-5 ring β-acid compounds, including those with the structural formula shown in formula (6), is 51-53 min.

9. The preparation method according to claim 2, characterized in that, In step S2, the extract is suspended in 8-15 times its weight of water and then extracted with dichloromethane.

10. The preparation method according to claim 2, characterized in that, In step S3, based on a total volume of 100, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when washing out fraction C is (58:42)-(62:38).

11. The preparation method according to claim 2, characterized in that, In step S3, based on a total volume of 100, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when washing out fraction C is 60:

40.

12. The preparation method according to claim 2, characterized in that, In step S4, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when washing out fraction C20 is (16:84)-(19:81). The volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when the C21 fraction is washed out is (14:86)-(16:84).

13. The preparation method according to claim 2, characterized in that, In step S4, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when washing out fraction C20 is 17:

83. The volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate solution when washing out fraction C21 is 15:

85.

14. The preparation method according to claim 2, characterized in that, In step S5, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate fraction C20.9 is (35:65)-(45:55).

15. The preparation method according to claim 2, characterized in that, In step S5, the volume ratio of petroleum ether to ethyl acetate in the petroleum ether-ethyl acetate fraction C20.9 is 40:

60.

16. The preparation method according to claim 2, characterized in that, In step S6, the volume ratio of dichloromethane to methanol in the dichloromethane-methanol solution when washing out fraction C21.2 is (6:4)-(3:7).

17. The preparation method according to claim 2, characterized in that, In step S6, the volume ratio of dichloromethane to methanol in the dichloromethane-methanol solution when washing out fraction C21.2 is 5:

5.

18. The preparation method according to claim 2, characterized in that, The solvent added is 8-10 times the mass of hops, and the reflux extraction is performed 1-3 times, with each extraction lasting 1-3 hours.

19. A pharmaceutical composition, characterized in that, It comprises the compound of claim 1.

20. The pharmaceutical composition according to claim 19, characterized in that, The pharmaceutical composition includes other components and pharmacodynamically acceptable carriers or excipients.

21. The pharmaceutical composition according to claim 20, characterized in that, The other components are one or more of the following substances: Aspirin, ibuprofen, indomethacin, naproxen, nabumetone, piroxicam, phenylbutazone, diclofenac, fenprofen, ketobuprofen, ketorolac, tetraclofenamic acid, sulindac, tometidine, fenbufen, sulindac, celecoxib, dexamethasone, prednisone, methylprednisolone, cortisone.

22. The pharmaceutical composition according to claim 19, characterized in that, The dosage form of the pharmaceutical composition is tablets, capsules, granules, oral liquids, powders, drops, or micro-pellets.

23. The use of the compound of claim 1 and / or the composition of any one of claims 19-22 in the preparation of a medicament for treating neuroinflammatory diseases, specifically depression, Alzheimer's disease, Parkinson's syndrome, Huntington's disease, neuromyelitis optica, and peripheral neuritis.

Citation Information

Patent Citations

  • Application of Humunus Lupulus L's effective part in preparation of drugs for preventing and improving anxiety and its clinical symptoms

    CN103285087A

  • Novel chalcone compound as well as preparation method, pharmaceutical composition and application thereof

    CN118666663A